Eli Lilly and Company (LLY)

$1,080.36 +5.68 (0.53%)
Market Cap 1,015.99B
Revenue (ttm) 45.04B
Net Income (ttm) 10.59B
EPS (ttm) N/A
PE Ratio 49.10
Forward PE 45.08
Profit Margin 23.51%
Debt to Equity Ratio 1.71
Volume 2,469,000
Avg Vol 3,648,866
Day's Range N/A - N/A
Shares Out 945.38M
Stochastic %K 78%
Beta 0.37
Analysts Strong Sell
Price Target $1,117.08

Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncolog...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 317 276 2000
Address:
Lilly Corporate Center, Indianapolis, United States
biolover
biolover Jan. 3 at 8:51 PM
$LLY ones who are bashing Lilly for $NVO on Lilly board just lost most of their saving in novo and never learned.
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Jan. 3 at 8:38 PM
$LLY – Still Bullish, But Watch Entry 🚀 $LLY remains strong and could keep breaking out. My system flagged it as a buy back in Oct–Nov with upside toward $1300 (~30% from then). At current levels, reward vs. risk is less attractive. Best to wait for a pullback unless you’re comfortable paying a premium. Full analysis here! It's free👉 @StockAnalyst_SA $UAMY $NLST $ALT $BABA
0 · Reply
Bargainhunters
Bargainhunters Jan. 3 at 8:11 PM
$LLY the game is changing to novo nordisk back again
0 · Reply
biolover
biolover Jan. 3 at 7:22 PM
$VKTX Vk2735 is effective and safe. The right question if in line with $LLY or significantly better which I expect the latter based on cumulative data and what is emerging from vanquish phase 3
1 · Reply
PaulBurke55
PaulBurke55 Jan. 3 at 4:49 PM
$LLY $ROST $GDDY $SBSW $DJT The market rhythm is firmly in the hands of the bulls.
0 · Reply
RunnersOnly4
RunnersOnly4 Jan. 3 at 4:41 PM
$LLY BUY NVO! From a value perspective, NVO is currently a "compressed spring," trading at a deeply discounted forward P/E ratio of approximately 14x, compared to LLY’s much loftier 27x–34x. By switching to NVO, investors are essentially moving from a stock priced for perfection into a "value-play" leader that is positioned to double in price as it transitions from 2025’s manufacturing hurdles to a new era of high-margin, volume-driven growth powered by the world’s first widely available weight-loss pill.
0 · Reply
Makingmillions192
Makingmillions192 Jan. 3 at 3:54 PM
$LEXX Hearing additional MTA partner speculation on my end. $LLY stands out as the best potential additional MTA partner because DehydraTECH directly addresses Lilly’s biggest unmet need: making large, complex incretin peptides orally viable without unacceptable GI side effects. Unlike Novo, Lilly is not locked into SNAC or a proprietary oral delivery solution, giving it flexibility to evaluate an external platform. Tirzepatide and next-generation dual or triple agonists are larger and harder to absorb than semaglutide, increasing the value of a lipid-based delivery system that can improve absorption efficiency and smooth exposure. GI tolerability is a known limitation for incretins, and Lexaria’s human data already shows meaningful reductions in GI adverse events. Strategically, Lilly has shown willingness to partner externally when it accelerates timelines, and oral incretins remain a major growth opportunity. Things could heat up fast with $NVO & $LLY involved here 💰
1 · Reply
biolover
biolover Jan. 3 at 2:57 PM
$VKTX look at 2025 q3 vs q2 big institutions ownership. If it were not FMR sale to save the shorts post data , Vk could have been $60 by now just from coverage. They reached 32% SI . . Most institutions actually increased positions post Aug data. most noted JPM by 95% or 2.5 M shares. This is very positive as I am sure JPM communicates with their health unit with such large acquisition and thus placed Viking with the best biotechs on meeting Monday schedule .. FMR sold Vk at $25 and it is the one lifted $GPCR from pre market drop post data and caused squeeze . I will remind you when $LLY starts reporting G4 ALT elevation in q2 q3 and what would happen to this FMR move.
2 · Reply
H8shorts
H8shorts Jan. 3 at 12:31 PM
$LLY money from here will soon move over to novo
0 · Reply
Bargainhunters
Bargainhunters Jan. 3 at 7:45 AM
$LLY has peaked.. NVO just started… move into the moving train, otherwise you will be at the same platform in this year
0 · Reply
Latest News on LLY
Top 15 High-Growth Dividend Stocks For January 2026

Jan 2, 2026, 7:44 PM EST - 20 hours ago

Top 15 High-Growth Dividend Stocks For January 2026

ACN APH AVGO BMI CDW CMCSA DHR

In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s

Dec 31, 2025, 3:08 PM EST - 3 days ago

In the Year of the Weight-Loss Pill, Lilly Still Leads GLP-1s

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

Dec 31, 2025, 6:08 AM EST - 3 days ago

Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump

GSK NVS PFE SNY

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

Dec 26, 2025, 10:35 PM EST - 7 days ago

Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January

CVX KMB ABM ABT AMGN AVGO BCPC

GLP-1 weight-loss pills set to reshape US food demand in 2026

Dec 24, 2025, 9:21 AM EST - 10 days ago

GLP-1 weight-loss pills set to reshape US food demand in 2026

NVO

Focus: Lilly, Novo lock horns in India's obesity drug race

Dec 23, 2025, 8:06 PM EST - 10 days ago

Focus: Lilly, Novo lock horns in India's obesity drug race

NVO

US health agency to expand access to GLP-1 weight-loss drugs

Dec 23, 2025, 4:56 PM EST - 10 days ago

US health agency to expand access to GLP-1 weight-loss drugs

NVO

Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback

Dec 23, 2025, 8:54 AM EST - 11 days ago

Eli Lilly Vs. Novo Nordisk: Which Stock Could Lead Pharma's 2026 Comeback

NVO

Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy

Dec 23, 2025, 6:41 AM EST - 11 days ago

Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy

ABVX

Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

Dec 23, 2025, 6:30 AM EST - 11 days ago

Eli Lilly Stock Falls. Novo Nordisk Got a Wegovy Weight-Loss Pill Approved in U.S.

NVO

Our Top 10 High-Growth Dividend Stocks - December 2025

Dec 20, 2025, 8:00 AM EST - 14 days ago

Our Top 10 High-Growth Dividend Stocks - December 2025

APH AU AVGO BK CCJ CIB CINF

Graham: A.I. & Fed Top 2026 Themes, Top Picks in ANET, COHR & LLY

Dec 19, 2025, 3:00 PM EST - 15 days ago

Graham: A.I. & Fed Top 2026 Themes, Top Picks in ANET, COHR & LLY

ANET COHR

Trump to announce new drug-pricing deals later today

Dec 19, 2025, 10:45 AM EST - 15 days ago

Trump to announce new drug-pricing deals later today

ABBV AMGN AZN BMY GILD MRK NVO

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026

Dec 19, 2025, 7:23 AM EST - 15 days ago

Mounjaro Maker Eli Lilly Improves In Quality As BofA Sees 'Room For Stock Upside' With $3 Billion In Sales By 2026

Thursday's Final Takeaways: Tech's Comeback & LLY Oral GLP-1 Drug

Dec 18, 2025, 5:00 PM EST - 15 days ago

Thursday's Final Takeaways: Tech's Comeback & LLY Oral GLP-1 Drug

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound.

Dec 18, 2025, 5:00 PM EST - 15 days ago

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound.

Obesity pill race heats up

Dec 18, 2025, 3:55 PM EST - 16 days ago

Obesity pill race heats up

Lose Weight on Zepbound, Keep It Off With Eli Lilly's New Pill? Data Say That Works.

Dec 18, 2025, 11:54 AM EST - 16 days ago

Lose Weight on Zepbound, Keep It Off With Eli Lilly's New Pill? Data Say That Works.

After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss

Dec 18, 2025, 11:29 AM EST - 16 days ago

After Wegovy, Zepbound Shots, This Eli Lilly Oral Pill Can Help Maintain Weight Loss

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Dec 18, 2025, 6:45 AM EST - 16 days ago

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

Dec 18, 2025, 6:45 AM EST - 16 days ago

Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial

Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

Dec 17, 2025, 11:56 PM EST - 16 days ago

Eli Lilly cuts price of diabetes, weight-loss drugs in Canada, Globe and Mail reports

AbbVie, several other pharma companies near MFN deal with Trump, sources say

Dec 17, 2025, 4:11 PM EST - 17 days ago

AbbVie, several other pharma companies near MFN deal with Trump, sources say

ABBV AMGN AZN BMY NVS PFE

Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.

Dec 17, 2025, 2:28 PM EST - 17 days ago

Eli Lilly's stock has crushed Nvidia's in recent weeks. What history has to say about that.

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

Dec 16, 2025, 2:29 PM EST - 18 days ago

Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly

NVO

LLY Leading Weight Loss Trade, Hold Economic "Trickle Down Effect"

Dec 16, 2025, 12:00 PM EST - 18 days ago

LLY Leading Weight Loss Trade, Hold Economic "Trickle Down Effect"

Lilly to participate in J.P. Morgan Healthcare Conference

Dec 16, 2025, 10:00 AM EST - 18 days ago

Lilly to participate in J.P. Morgan Healthcare Conference

Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

Dec 16, 2025, 6:48 AM EST - 18 days ago

Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars

NVO

Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says

Dec 15, 2025, 12:05 PM EST - 19 days ago

Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Dec 15, 2025, 4:31 AM EST - 19 days ago

Eli Lilly: Short-Term Upside Exhausted (Rating Downgrade)

Eli Lilly: The Right Long-Term Strategy

Dec 13, 2025, 4:33 AM EST - 21 days ago

Eli Lilly: The Right Long-Term Strategy

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

Dec 12, 2025, 11:45 AM EST - 22 days ago

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

Thursday's Final Takeaways: LLY Positive Drug Trial, Home Prices Turn Negative

Dec 11, 2025, 5:26 PM EST - 22 days ago

Thursday's Final Takeaways: LLY Positive Drug Trial, Home Prices Turn Negative

Eli Lilly's Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.

Dec 11, 2025, 11:23 AM EST - 23 days ago

Eli Lilly's Latest Obesity Drug Delivers Strong Results. It Might Work Too Well.

New Lilly Shot Reduces Body Weight by 23% in Study

Dec 11, 2025, 10:59 AM EST - 23 days ago

New Lilly Shot Reduces Body Weight by 23% in Study

GOOGL Price Target Raise, SNPS Strong Guidance, LLY Retratrutide Results

Dec 11, 2025, 10:15 AM EST - 23 days ago

GOOGL Price Target Raise, SNPS Strong Guidance, LLY Retratrutide Results

GOOG GOOGL SNPS

Eli Lilly's newest weight-loss drug relieved pain in patients with knee osteoarthritis

Dec 11, 2025, 7:55 AM EST - 23 days ago

Eli Lilly's newest weight-loss drug relieved pain in patients with knee osteoarthritis

Eli Lilly Reports Positive Results From Study of Weight Loss Drug

Dec 11, 2025, 7:54 AM EST - 23 days ago

Eli Lilly Reports Positive Results From Study of Weight Loss Drug

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

Dec 11, 2025, 7:39 AM EST - 23 days ago

Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly

NVO

Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial

Dec 11, 2025, 6:49 AM EST - 23 days ago

Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trial

Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial

Dec 11, 2025, 6:45 AM EST - 23 days ago

Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Dec 11, 2025, 6:45 AM EST - 23 days ago

Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial

Microsoft, Broadcom, Lilly, and Other Stocks That Define ‘Quality' for This Pro

Dec 11, 2025, 2:00 AM EST - 23 days ago

Microsoft, Broadcom, Lilly, and Other Stocks That Define ‘Quality' for This Pro

AVGO MSFT

Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost Production

Dec 10, 2025, 4:45 PM EST - 23 days ago

Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost Production

French biotech Abivax's shares climb on Eli Lilly bid rumors

Dec 10, 2025, 5:52 AM EST - 24 days ago

French biotech Abivax's shares climb on Eli Lilly bid rumors

ABVX

Eli Lilly to Build $6 Billion Alabama Plant as Part of U.S. Investment

Dec 9, 2025, 3:59 PM EST - 25 days ago

Eli Lilly to Build $6 Billion Alabama Plant as Part of U.S. Investment

Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push

Dec 9, 2025, 3:34 PM EST - 25 days ago

Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Dec 9, 2025, 3:30 PM EST - 25 days ago

Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

Dec 9, 2025, 3:30 PM EST - 25 days ago

Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

Dec 9, 2025, 8:28 AM EST - 25 days ago

Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition

ADVM

biolover
biolover Jan. 3 at 8:51 PM
$LLY ones who are bashing Lilly for $NVO on Lilly board just lost most of their saving in novo and never learned.
0 · Reply
StockAnalyst_SA
StockAnalyst_SA Jan. 3 at 8:38 PM
$LLY – Still Bullish, But Watch Entry 🚀 $LLY remains strong and could keep breaking out. My system flagged it as a buy back in Oct–Nov with upside toward $1300 (~30% from then). At current levels, reward vs. risk is less attractive. Best to wait for a pullback unless you’re comfortable paying a premium. Full analysis here! It's free👉 @StockAnalyst_SA $UAMY $NLST $ALT $BABA
0 · Reply
Bargainhunters
Bargainhunters Jan. 3 at 8:11 PM
$LLY the game is changing to novo nordisk back again
0 · Reply
biolover
biolover Jan. 3 at 7:22 PM
$VKTX Vk2735 is effective and safe. The right question if in line with $LLY or significantly better which I expect the latter based on cumulative data and what is emerging from vanquish phase 3
1 · Reply
PaulBurke55
PaulBurke55 Jan. 3 at 4:49 PM
$LLY $ROST $GDDY $SBSW $DJT The market rhythm is firmly in the hands of the bulls.
0 · Reply
RunnersOnly4
RunnersOnly4 Jan. 3 at 4:41 PM
$LLY BUY NVO! From a value perspective, NVO is currently a "compressed spring," trading at a deeply discounted forward P/E ratio of approximately 14x, compared to LLY’s much loftier 27x–34x. By switching to NVO, investors are essentially moving from a stock priced for perfection into a "value-play" leader that is positioned to double in price as it transitions from 2025’s manufacturing hurdles to a new era of high-margin, volume-driven growth powered by the world’s first widely available weight-loss pill.
0 · Reply
Makingmillions192
Makingmillions192 Jan. 3 at 3:54 PM
$LEXX Hearing additional MTA partner speculation on my end. $LLY stands out as the best potential additional MTA partner because DehydraTECH directly addresses Lilly’s biggest unmet need: making large, complex incretin peptides orally viable without unacceptable GI side effects. Unlike Novo, Lilly is not locked into SNAC or a proprietary oral delivery solution, giving it flexibility to evaluate an external platform. Tirzepatide and next-generation dual or triple agonists are larger and harder to absorb than semaglutide, increasing the value of a lipid-based delivery system that can improve absorption efficiency and smooth exposure. GI tolerability is a known limitation for incretins, and Lexaria’s human data already shows meaningful reductions in GI adverse events. Strategically, Lilly has shown willingness to partner externally when it accelerates timelines, and oral incretins remain a major growth opportunity. Things could heat up fast with $NVO & $LLY involved here 💰
1 · Reply
biolover
biolover Jan. 3 at 2:57 PM
$VKTX look at 2025 q3 vs q2 big institutions ownership. If it were not FMR sale to save the shorts post data , Vk could have been $60 by now just from coverage. They reached 32% SI . . Most institutions actually increased positions post Aug data. most noted JPM by 95% or 2.5 M shares. This is very positive as I am sure JPM communicates with their health unit with such large acquisition and thus placed Viking with the best biotechs on meeting Monday schedule .. FMR sold Vk at $25 and it is the one lifted $GPCR from pre market drop post data and caused squeeze . I will remind you when $LLY starts reporting G4 ALT elevation in q2 q3 and what would happen to this FMR move.
2 · Reply
H8shorts
H8shorts Jan. 3 at 12:31 PM
$LLY money from here will soon move over to novo
0 · Reply
Bargainhunters
Bargainhunters Jan. 3 at 7:45 AM
$LLY has peaked.. NVO just started… move into the moving train, otherwise you will be at the same platform in this year
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Jan. 3 at 1:43 AM
Enter: $LLY Calls Strike Price: $1075 Expiry Date: JAN 23 2026 Buy in Price: $27.21 - $30.65 Sell Price: $43.26 Profit : +59% (Turn every $1 into $1.59) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/pricing
0 · Reply
PaulBurke55
PaulBurke55 Jan. 2 at 11:40 PM
$LLY $DGNX $TQQQ $EA $TSLA After breaking through key resistance, the price launched a sharp offensive.
0 · Reply
Bargainhunters
Bargainhunters Jan. 2 at 9:43 PM
$LLY loss = NVO gain
1 · Reply
ElliottwaveForecast
ElliottwaveForecast Jan. 2 at 9:35 PM
How much clarity would you gain if you knew the next high‑probability upside zone in $LLY? The structure continues to support a bullish path toward 1144.4–1196.17 as long as the pivot holds. Check out this 👉 elliottwave-forecast.com/stock-market/lly-buyers-looking-for-rally-1144-4-1196-17#Trading #LLY #ElliottWave #Markets
0 · Reply
Ray89c
Ray89c Jan. 2 at 8:51 PM
$ALUR wow this got legs back $LLY $NVO $IRWD
0 · Reply
Impatient_Investor
Impatient_Investor Jan. 2 at 8:21 PM
$LLY
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 2 at 7:55 PM
$LEXX $NVO $LLY $MRK
0 · Reply
Impatient_Investor
Impatient_Investor Jan. 2 at 7:19 PM
$LLY every slight drop is a trap for retailers to take short position.
0 · Reply
ProfessorDman1
ProfessorDman1 Jan. 2 at 7:09 PM
$MGRX $MGRX Mangoceuticals, Inc. Announces Partnership with The Cube Group to Launch Up To $100 Million Solana-Focused Digital Asset Treasury (DAT) Strategy recent headline December 2025 and also in November 2025 news with $LLY and $NVO.. should see some updates here ..
1 · Reply
Makingmillions192
Makingmillions192 Jan. 2 at 7:09 PM
$LEXX $NVO $PFE $LLY I can imagine there are big things in the works now that phase 1b data is out. Lily or Pfizer would be nuts to let Novo get their hands on this technology… 💰
0 · Reply
Turbofueled
Turbofueled Jan. 2 at 3:38 PM
$LEXX Recap- This is going to go wild!!🌋🚀💥 $NVO $LLY $MRK Its up from here! https://lexariabioscience.com/2025/12/23/primary-endpoint-successfully-achieved-in-lexarias-phase-1b-study-glp-1-h24-4/
1 · Reply
Bargainhunters
Bargainhunters Jan. 2 at 2:40 PM
$LLY novo gain = Lly loss
0 · Reply